ENDRA Life Sciences (NDRA) Competitors $4.58 +0.19 (+4.33%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends NDRA vs. PXDT, PETV, PAVM, STRR, ICU, TTOO, NURO, BTCY, CUTR, and PSTVShould you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include Pixie Dust Technologies (PXDT), PetVivo (PETV), PAVmed (PAVM), Star Equity (STRR), SeaStar Medical (ICU), T2 Biosystems (TTOO), NeuroMetrix (NURO), Biotricity (BTCY), Cutera (CUTR), and Plus Therapeutics (PSTV). These companies are all part of the "medical equipment" industry. ENDRA Life Sciences vs. Pixie Dust Technologies PetVivo PAVmed Star Equity SeaStar Medical T2 Biosystems NeuroMetrix Biotricity Cutera Plus Therapeutics ENDRA Life Sciences (NASDAQ:NDRA) and Pixie Dust Technologies (NASDAQ:PXDT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings. Is NDRA or PXDT more profitable? Pixie Dust Technologies' return on equity of 0.00% beat ENDRA Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets ENDRA Life SciencesN/A -127.39% -103.77% Pixie Dust Technologies N/A N/A N/A Which has more risk and volatility, NDRA or PXDT? ENDRA Life Sciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Pixie Dust Technologies has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Does the MarketBeat Community prefer NDRA or PXDT? ENDRA Life Sciences received 235 more outperform votes than Pixie Dust Technologies when rated by MarketBeat users. However, 100.00% of users gave Pixie Dust Technologies an outperform vote while only 62.77% of users gave ENDRA Life Sciences an outperform vote. CompanyUnderperformOutperformENDRA Life SciencesOutperform Votes23662.77% Underperform Votes14037.23% Pixie Dust TechnologiesOutperform Votes1100.00% Underperform VotesNo Votes Which has higher valuation & earnings, NDRA or PXDT? ENDRA Life Sciences has higher earnings, but lower revenue than Pixie Dust Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioENDRA Life SciencesN/AN/A-$10.06M-$901.15-0.01Pixie Dust Technologies$993.02M0.01-$12.53MN/AN/A Does the media refer more to NDRA or PXDT? In the previous week, Pixie Dust Technologies had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 1 mentions for Pixie Dust Technologies and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 1.87 beat Pixie Dust Technologies' score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the media. Company Overall Sentiment ENDRA Life Sciences Very Positive Pixie Dust Technologies Neutral Do insiders and institutionals hold more shares of NDRA or PXDT? 1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 0.4% of Pixie Dust Technologies shares are owned by institutional investors. 0.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer NDRA or PXDT? ENDRA Life Sciences presently has a consensus target price of $700,000.00, indicating a potential upside of 15,283,742.79%. Pixie Dust Technologies has a consensus target price of $5.21, indicating a potential upside of 798.28%. Given ENDRA Life Sciences' higher probable upside, equities analysts plainly believe ENDRA Life Sciences is more favorable than Pixie Dust Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Pixie Dust Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryENDRA Life Sciences beats Pixie Dust Technologies on 7 of the 12 factors compared between the two stocks. Ad Crypto 101 MediaDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Claim your FREE book now before it's too late! Get ENDRA Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NDRA vs. The Competition Export to ExcelMetricENDRA Life SciencesElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.46M$3.04B$5.19B$9.32BDividend YieldN/A1.73%4.78%4.06%P/E Ratio-0.0118.50128.2217.54Price / SalesN/A54.581,259.00139.66Price / CashN/A39.9141.2237.95Price / Book0.003.754.884.92Net Income-$10.06M$90.26M$119.69M$225.78M7 Day Performance-3.98%-3.87%16.64%-1.56%1 Month Performance9.83%2.12%16.32%6.68%1 Year Performance-100.00%8.57%35.37%22.48% ENDRA Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NDRAENDRA Life Sciences2.3752 of 5 stars$4.58+4.3%$700,000.00+15,283,742.8%-100.0%$2.46MN/A-0.0120Positive NewsGap UpPXDTPixie Dust Technologies1.5283 of 5 stars$0.58+9.2%$5.21+798.4%N/A$8.62M$993.02M0.0078High Trading VolumePETVPetVivoN/A$0.41-0.9%N/A-51.6%$8.36M$970,000.00-0.8520PAVMPAVmed4.146 of 5 stars$0.75-2.6%$19.00+2,450.3%-81.7%$8.25M$2.45M-0.1890STRRStar Equity1.3005 of 5 stars$2.53-3.8%N/A-53.3%$8.14M$50.38M-1.02171Gap UpHigh Trading VolumeICUSeaStar Medical0.2942 of 5 stars$1.82-8.5%N/A-84.2%$8.12M$68,000.00-0.172Gap DownTTOOT2 Biosystems2.9378 of 5 stars$0.37+1.4%$5.00+1,250.6%-91.0%$7.79M$7.19M0.00180News CoverageGap UpHigh Trading VolumeNURONeuroMetrix1.0715 of 5 stars$3.80-0.3%N/A+5.1%$7.76M$3.77M-0.8320News CoverageBTCYBiotricityN/A$0.29-8.3%N/A-71.6%$7.12M$12.06M-0.2340CUTRCutera1.5712 of 5 stars$0.35-2.5%$3.00+757.1%-87.5%$7.07M$155.21M-0.05430Short Interest ↑Gap DownPSTVPlus Therapeutics1.6988 of 5 stars$1.19-6.3%$13.50+1,034.5%-44.0%$7.02M$4.91M-0.5020News Coverage Related Companies and Tools Related Companies Pixie Dust Technologies Competitors PetVivo Competitors PAVmed Competitors Star Equity Competitors SeaStar Medical Competitors T2 Biosystems Competitors NeuroMetrix Competitors Biotricity Competitors Cutera Competitors Plus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NDRA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
